4,199 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Perbak Capital Partners LLP

Perbak Capital Partners LLP purchased a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,199 shares of the medical research company's stock, valued at approximately $1,379,000.

Other hedge funds also recently bought and sold shares of the company. Metis Global Partners LLC boosted its position in shares of Bio-Rad Laboratories by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock worth $234,000 after buying an additional 30 shares during the period. Signaturefd LLC boosted its holdings in Bio-Rad Laboratories by 13.2% during the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock valued at $87,000 after acquiring an additional 31 shares during the period. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after acquiring an additional 32 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Bio-Rad Laboratories by 0.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock valued at $1,488,000 after acquiring an additional 32 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Bio-Rad Laboratories by 3.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BIO shares. Royal Bank of Canada cut their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday. UBS Group decreased their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Finally, Citigroup decreased their target price on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research note on Friday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $327.40.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock traded down $3.60 during midday trading on Friday, hitting $236.83. 697,416 shares of the company's stock were exchanged, compared to its average volume of 320,682. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a market cap of $6.63 billion, a price-to-earnings ratio of -3.64 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a 12-month low of $215.38 and a 12-month high of $387.99. The firm's 50 day simple moving average is $246.93 and its 200 day simple moving average is $304.95.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The firm had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. During the same quarter in the previous year, the firm posted $2.30 EPS. The firm's revenue for the quarter was down 4.2% on a year-over-year basis. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.